FREE REPORT: FATE THERAPEUTICS

Free Report: [Revisting A 'Five…

We did a piece on immunotherapy play Fate Therapeutics (FATE) just over a year ago. It was one of the first free reports we published. That positive profile and recommendation came out when the shares traded right at $3.00 a share. As you can see from the chart below, it was one of the better calls of the last year. Today, we follow up with another piece on this biotech concern which despite its recent huge rally has seen some notable insider buying of late. Click here to download

Comments


Bret Jensen
EditorBret Jensen
alexandra
Editoralexandra
New Comment
1
Bret Jensen
EditorBret Jensen
New Comment
allisondbl
1
Bret Jensen
EditorBret Jensen
New Comment
fadiwd
Bret Jensen
EditorBret Jensen
New Comment
Timothy Blackbread
alexandra
Editoralexandra
New Comment
Bret Jensen
EditorBret Jensen
New Comment
altheqa
Bret Jensen
EditorBret Jensen
New Comment
Bret Jensen
EditorBret Jensen
New Comment